Akari Therapeutics, Plc (AKTX) Stock Score, Valuation & Financial Research

Akari Therapeutics, Plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AKTX

Akari Therapeutics, Plc does not currently have a complete Wall Street Score. The stored market price is USD 8.39. These figures are a research snapshot, not a buy or sell recommendation.

What Akari Therapeutics, Plc does

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Akari Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on the research, development, and potential future commercialization of innovative therapeutics for rare and orphan autoimmune and inflammatory diseases, funded primarily through equity financing and capital raises.

Products and services

  • The company is developing nomacopan, a clinical-stage small molecule inhibitor of complement C5 and leukotriene B4, intended for the treatment of rare autoimmune and inflammatory conditions.

Customer types

Patients with rare and orphan autoimmune and inflammatory diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, drug substance manufacturing, and supply chain logistics. Source

Business strengths to evaluate

  • Proprietary small molecule drug discovery platform targeting complement C5 and LTB4 Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to fund operations Source
  • Risks associated with clinical trial success, regulatory approval, and manufacturing scalability Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AKTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.39
Market capitalization:
9.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -30.96M
Free cash flow:
USD -10.57M
Cash:
USD 7.69M
Total debt:
USD 693K
EPS:
USD -1600.00

What stands out

  • Free cash flow is USD -10.57M, negative for the stored period.
  • The balance sheet shows USD 7.69M of cash versus USD 693K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AKTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AKTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AKTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AKTX to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of AKTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AKTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.